Welcome to our dedicated page for The Cooper Companies news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on The Cooper Companies stock.
The Cooper Companies, Inc. (NYSE: COO) is a global medical device company specializing in improving quality of life through innovative products and services. Headquartered in San Ramon, CA, Cooper operates through two main business units: CooperVision and CooperSurgical.CooperVision is a leader in the contact lens industry, offering a diverse range of high-quality contact lenses, including spherical, multifocal, toric, and specialty lenses. With brands like Proclear, Biofinity, MyDay, and Clariti, CooperVision commands roughly one-fourth of the US contact lens market. The company is committed to providing excellent practitioner support, ensuring that both users and professionals benefit from their cutting-edge solutions.
CooperSurgical, founded in 1990, focuses on women's health and fertility, offering market-leading products and treatment options. The division supplies clinicians with over 600 medical devices and treatment solutions related to reproductive care, fertility, and women's health. Notably, CooperSurgical owns Paragard, the only hormone-free IUD available in the US, holding a 17% share of the US IUD market. Additionally, CooperSurgical has the largest medical device coverage for the entire IVF cycle.
With a workforce of over 15,000 employees and products available in more than 130 countries, CooperCompanies is dedicated to delivering shareholder value while enhancing the lives of individuals globally. The company continues to innovate and expand, recently achieving record annual revenues and strong earnings. Noteworthy advancements include a four-for-one stock split set to become effective on February 16, 2024, and partnerships like that with Fulgent Genetics to offer exclusive newborn genetic screening panels through Cord Blood Registry.
Cooper's fiscal year 2023 showcased significant milestones, including double-digit organic growth in their fertility segment and strong performance in contact lenses. As they move into fiscal year 2024, Cooper remains focused on their strategic objectives: gaining market share, driving profitability, and launching innovative products and services.
For more information, please visit CooperCompanies.
Rhea-AI Summary
CooperCompanies (COO) will report its first quarter 2024 financial results on February 29, 2024, at 4:15 PM ET. The Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 5337119. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) to participate at J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
Rhea-AI Summary
Cooper Companies (Nasdaq: COO) to hold annual meeting of stockholders on March 19, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) announced fiscal fourth quarter 2023 revenue of $927.1 million, up 9%, with a GAAP diluted EPS of $1.70, up 29%. Fiscal year 2023 revenue was $3.6 billion, up 9%. The company's board approved a four-for-one stock split, and fiscal 2024 financial guidance includes a total revenue of $3,809 - $3,877 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
-
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) appoints Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius brings a wealth of experience from his tenure as CEO and President of McCormick and Company, as well as his roles in other global organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
-
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) will report Q4 and full year 2023 financial results on December 7, 2023, at 4:15 PM ET. A conference call will be held at 5:00 PM ET to discuss the results and current corporate developments. Dial-in number: 800-715-9871, conference ID: 3206652. Audio webcast available at http://investor.coopercos.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
Rhea-AI Summary
CooperCompanies has completed the acquisition of select Cook Medical assets for a purchase price of $300 million. The acquired assets are focused on the obstetrics, doppler monitoring, and gynecology surgery markets. The assets generated $56 million in revenue in the past twelve months and are expected to contribute to a 5-7% year-over-year revenue growth in fiscal year 2024. The transaction is expected to be accretive to non-GAAP gross and operating margins and non-GAAP earnings per share by approximately $0.20.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
-
Rhea-AI Summary
CooperCompanies will transfer its listing from NYSE to Nasdaq, trading as a Nasdaq-listed company starting September 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
-
Rhea-AI Summary
CooperCompanies to participate in Baird Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
Rhea-AI Summary
CooperSurgical's Cord Blood Registry (CBR) will play a key role in the Cord Blood Connect meeting, presenting new scientific data and moderating a forum on the future of cord blood banking. CBR's Newborn Possibilities Program is effective in identifying families likely to use cord blood units for transplants or infusions. Cord blood banks should re-evaluate eligibility criteria. CooperSurgical aims to expand access to more families as the science evolves. Moderating a panel on the future of cord blood banking, CBR will discuss challenges and opportunities in the industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
FAQ
What is the current stock price of The Cooper Companies (COO)?
The current stock price of The Cooper Companies (COO) is $93.44 as of December 20, 2024.
What is the market cap of The Cooper Companies (COO)?
The market cap of The Cooper Companies (COO) is approximately 18.6B.
What does The Cooper Companies, Inc. specialize in?
The Cooper Companies, Inc. specializes in medical devices through its two business units, CooperVision and CooperSurgical. CooperVision focuses on contact lenses, while CooperSurgical offers products related to fertility and women's health.
Where is The Cooper Companies, Inc. headquartered?
The Cooper Companies, Inc. is headquartered in San Ramon, California.
What are some of CooperVision's popular contact lens brands?
CooperVision's popular contact lens brands include Proclear, Biofinity, MyDay, and Clariti.
What makes CooperSurgical unique in the women's health market?
CooperSurgical is unique for its comprehensive range of products covering the entire IVF cycle and for being the only provider of the hormone-free IUD, Paragard, in the US.
How many employees does The Cooper Companies, Inc. have?
The Cooper Companies, Inc. employs more than 15,000 people globally.
What recent financial achievements has CooperCompanies reported?
CooperCompanies reported record annual revenues for fiscal year 2023, driven by gains in contact lenses and fertility. They also announced a four-for-one stock split effective February 16, 2024.
In how many countries are CooperCompanies’ products available?
CooperCompanies’ products are available in over 130 countries.
What recent partnerships has CooperSurgical announced?
CooperSurgical recently partnered with Fulgent Genetics to offer exclusive newborn genetic screening panels through Cord Blood Registry.
What are CooperCompanies' strategic objectives for fiscal year 2024?
CooperCompanies' strategic objectives for fiscal year 2024 include gaining market share, driving profitability, and launching innovative products and services.
Where can I find more information about The Cooper Companies, Inc.?
For more information about The Cooper Companies, Inc., please visit their official website at www.coopercos.com.
The Cooper Companies, Inc.
Nasdaq:COO
COO Rankings
COO Stock Data
18.57B
198.50M
0.54%
98.36%
1.11%
Medical Instruments & Supplies
Ophthalmic Goods
United States of America
SAN RAMON